文献速递瓣膜外科

二尖瓣手术的长期结局与抗凝治疗——来自胸外科医师学会数据库的报告

Long-term Outcomes and Anticoagulation in Mitral Valve Surgery-A Report From The Society of Thoracic Surgeons Database.
PubMed 文献 · Ann Thorac Surg · 2023-06-10

本研究基于胸外科医师学会成人心脏外科数据库,将年龄≥65岁的二尖瓣生物瓣置换(BMVR)和二尖瓣修复(MVrep)患者与联邦医疗保险索赔数据库链接,比较出院时抗凝状态对长期死亡、缺血性卒中、出血及复合终点的影响。结果显示,华法林与总体队列出血增加相关,仅在BMVR患者中与死亡降低相关;NOAC与死亡、出血及复合终点增加相关。

要点

  • 二尖瓣手术患者出院时抗凝使用率不足一半。
  • MVrep患者中,华法林与出血增加相关,且未降低卒中或死亡。
  • BMVR患者中,华法林与适度生存获益相关,但出血增加,卒中风险相当。

核心结论

  • 二尖瓣手术患者中抗凝使用不足一半;MVrep患者华法林与出血增加相关且未降低卒中或死亡;BMVR患者华法林与适度生存获益相关、出血增加、卒中风险相当;NOAC与不良结局增加相关。

研究设计与样本

  • 基于胸外科医师学会成人心脏外科数据库与联邦医疗保险索赔数据库链接的回顾性队列研究,纳入年龄≥65岁的BMVR和MVrep患者共26199例。

主要发现

  • 出院时华法林、NOAC和无抗凝(参照)分别占44%、4%和52%。
  • 华法林与总体队列出血增加相关(HR 1.38;95%CI 1.26-1.52),BMVR亚组(HR 1.32;95%CI 1.13-1.55)和MVrep亚组(HR 1.42;95%CI 1.26-1.60)均如此。
  • 华法林仅在BMVR患者中与死亡降低相关(HR 0.87;95%CI 0.79-0.96)。
  • 华法林组卒中及复合终点在各队列间无差异。
  • NOAC使用与死亡增加(HR 1.33;95%CI 1.11-1.59)、出血增加(HR 1.37;95%CI 1.07-1.74)及复合终点增加(HR 1.26;95%CI 1.08-1.47)相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anticoagulation after bioprosthetic mitral valve (MV) replacement (BMVR) and repair (MVrep) is controversial. We explore outcomes among BMVR and MVrep patients in The Society of Thoracic Surgeons Adult Cardiac Surgery Database based on discharge anticoagulation status. METHODS: BMVR and MVrep patients aged ≥65 years in The Society of Thoracic Surgeons Adult Cardiac Surgery Database were linked to the Centers for Medicare and Medicaid Services claims database. Long-term mortality, ischemic stroke, bleeding, and a composite of the primary end points were compared as a function of anticoagulation. Hazard ratios (HRs) were calculated using multivariable Cox regression. RESULTS: A total of 26,199 BMVR and MVrep patients were linked to the Centers for Medicare and Medicaid Services database; of these, 44%, 4%, and 52% were discharged on warfarin, non-vitamin K-dependent anticoagulant (NOAC), and no anticoagulation (no-AC; reference), respectively. Warfarin was associated with increased bleeding in the overall study cohort (HR, 1.38; 95% CI 1.26-1.52) and in the BMVR (HR, 1.32; 95% CI, 1.13-1.55) and MVrep subcohorts (HR, 1.42; 95% CI, 1.26-1.60). Warfarin was associated with decreased mortality only among BMVR patients (HR, 0.87; 95% CI, 0.79-0.96). Stroke and the composite outcome did not differ across cohorts with warfarin. NOAC use was associated with increased mortality (HR, 1.33; 95% CI 1.11-1.59), bleeding (HR, 1.37; 95% CI, 1.07-1.74), and the composite outcome (HR, 1.26; 95% CI, 1.08-1.47). CONCLUSIONS: Anticoagulation was used in fewer than half of mitral valve operations. In MVrep patients, warfarin was associated with increased bleeding and was not protective against stroke or mortality. In BMVR patients, warfarin was associated with a modest survival benefit, increased bleeding, and equivalent stroke risk. NOAC was associated with increased adverse outcomes.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Schwann TA, Vekstein AM, Engelman DT, et al. Long-term Outcomes and Anticoagulation in Mitral Valve Surgery-A Report From The Society of Thoracic Surgeons Database. Ann Thorac Surg. 2023. PMID: 37308066. doi:10.1016/j.athoracsur.2023.05.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。